Pharmaceutical companies have invested hundreds of millions of dollars in new HIV/AIDS treatments not out of altruism but because they can make up those research costs in sales.

Sick people, particularly those with serious conditions, greatly prefer the company of their friends and family to residence in a hospital or nursing home.

I love books, I love art, I'm a fanatic nature and wildlife person. People assume I'm a political animal, power hungry, wanting to run for office. And anyone who knows me knows that none of that's true.

Treating HIV/AIDS is a lifelong commitment that demands strict adherence to drug protocols, consistent care, and a trusting relationship with health care providers.

Over the years, HIV/AIDS activists and their allies have been pioneers in creating new frontiers in the medical establishment. Through their efforts, the FDA drug approval procedures were reformed so promising new therapies could reach desperate patients quicker.

I often laugh and say I should go down to the Department of the Interior and register as an endangered species. I'm a gay man over 60 and I'm alive.

Getting a traditional pharmaceutical to the market can cost a billion dollars or more. Newer, more tailored and targeted drugs called biologics are even more complex and expensive. Simple economics dictates that companies and venture funds will invest more in products that can generate a sufficient return.